BridGene Biosciences
Pioneering the next era of small molecules therapeutics
BridGene Biosciences is headquartered in United States and has $80.5M in recorded funding across 3 rounds.
- Business Model
- B2B
- Website
- bridgenebio.com
- Total Funding
- $80.5M
- Last Round
- $28.0M Series BOct 2025
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 5 investors for this company. The full record is or through the API.
About
Chemoproteomics-driven small-molecule drug R&D for undruggable targets
Summary
BridGene Biosciences is a Biotech company based in United States. It has raised $80.5M in total across 3 rounds, most recently a $28.0M Series B round in Oct 2025. Investors include Lapam Capital, Bayland Capital and GTJA Investment Group.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2025
Sign up to see all 3 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bridgene-biosciences"><img src="https://indexed.vc/api/badge/company/bridgene-biosciences" alt="BridGene Biosciences on Indexed.vc" width="260" height="76" /></a>